GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Sanofi (SNY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports first-quarter results.
GlaxoSmithKline (GSK) Stock Moves -1.61%: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $41.05, moving -1.61% from the previous trading session.
Can Lilly (LLY) Deliver a Beat in Coronavirus-Hit Q1 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports first-quarter results.
The Zacks Analyst Blog Highlights: Netflix, Costco, GlaxoSmithKline, Johnson & Johnson and Cigna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Costco, GlaxoSmithKline, Johnson & Johnson and Cigna
Gilead Increases Enrollment Target, Pharma Rally Continues
by Ritujay Ghosh
Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.
Regeneron's BLA for Ebola Vaccine Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts Regeneron's (REGN) BLA for REGN-EB3 under a priority review to treat the deadly Ebola virus infection. A verdict is pending on Oct 25, 2020.
Sanofi/Luminostics to Make Self-Testing Solution for Coronavirus
by Zacks Equity Research
Sanofi (SNY) partners with Luminostics to make a COVID-19 smartphone-based self-testing solution, which will be based on the latter's proprietary technology.
Moderna Rallies on US Government Grant for Coronavirus Vaccine
by Zacks Equity Research
Moderna (MRNA) gets a commitment of up to $483 million from the U.S. Government Agency BARDA to accelerate the development of its mRNA-based coronavirus vaccine.
Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts
by Kinjel Shah
J&J (JNJ) announces Q1 results. Several companies offer update on their studies/plans to make coronavirus treatments or vaccines
Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D
by Ritujay Ghosh
Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.
Q1 Earnings Scorecard and Analyst Reports for Netflix, Costco & Others
by Sheraz Mian
In addition to new research reports on 16 major stocks, including Netflix (NFLX), Costco (COST) and others, we also have real-time Q1 earnings scorecard today.
Sanofi and Glaxo Collaborate to Develop Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) and Glaxo are contributing their proven technologies to develop a coronavirus vaccine, which may be manufactured at large scale.
Pharma Q1 Earnings Begin With J&J's Report: 3 Stocks to Buy
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.
Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up
by Ritujay Ghosh
If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $38.08, marking a +1.47% move from the previous day.
Merck's Keytruda Gets FDA's Priority Review for Solid Tumors
by Zacks Equity Research
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress
by Sweta Jaiswal, FRM
The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Glaxo to Buy Stake in Vir Biotech, Signs Coronavirus Deal
by Zacks Equity Research
Glaxo (GSK) set to invest $250 million in Vir Biotechnology. Vir's stock soars.
Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement
by Zacks Equity Research
Myriad Genetics (MYGN) launches BRACAnalysis Diagnostic System in Japan, after receiving reimbursement for the system, which will enable easier identification of HBOC patients.
Glaxo's Nasal Polyps Study on Nucala Meets Primary Endpoints
by Zacks Equity Research
Glaxo's (GSK) phase III study on Nucala in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) meets co-primary endpoints.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure
by Kinjel Shah
Supply-chain disruptions due to coronavirus outbreak may hurt biotech companies' first-quarter earnings. However, those making treatments/vaccines may make huge profits if their products get approval.
Glaxo's Long-Acting HIV Regimen Cabenuva Gets Canada's Nod
by Kinjel Shah
Glaxo's (GSK) long-acting injectable regimen of cabotegravir and rilpivirine gets its first approval for the treatment of HIV-1 infection in virologically-suppressed adults
The Zacks Analyst Blog Highlights: ORCL, CSCO, NFLX, GSK and CCI
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ORCL, CSCO, NFLX, GSK and CCI
These 10 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.